<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04191551</url>
  </required_header>
  <id_info>
    <org_study_id>45077</org_study_id>
    <nct_id>NCT04191551</nct_id>
  </id_info>
  <brief_title>The GAstric Precancerous Conditions Study</brief_title>
  <acronym>GAPS</acronym>
  <official_title>The GAstric Precancerous Conditions Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gastric cancer afflicts 27,000 Americans annually and carries a dismal prognosis. One reason&#xD;
      for poor outcomes is late diagnosis, as the majority of gastric cancers in the United States&#xD;
      are diagnosed at a relatively advanced stage where curative resection is unlikely. Gastric&#xD;
      intestinal metaplasia (GIM) is a precancerous change of the stomach which increases risk for&#xD;
      subsequent gastric cancer multiple-fold.&#xD;
&#xD;
      The Gastric Precancerous Conditions Study (GAPS) is an observational study with two&#xD;
      over-arching objectives: 1) improve the non-invasive identification of patients with GIM, and&#xD;
      2) develop biological markers to predict the subset of GIM which will progress onto gastric&#xD;
      cancer.&#xD;
&#xD;
      To achieve Aim 1, a case-control study (N=300 pairs) matching cases of GIM with&#xD;
      age-/gender-matched controls will be recruited form the population of subjects undergoing&#xD;
      clinically-indicated endoscopy. Determination of gastric pathology will be made by two,&#xD;
      independent gastrointestinal pathologists. At time of endoscopy, a detailed clinical&#xD;
      questionnaire is administered by face-to-face interview. Saliva and blood is collected prior&#xD;
      to endoscopy. At time of endoscopy, protocoled clinical biopsies (per Revised Sydney&#xD;
      Protocol) as well as additional research specimens are collected. Scoring of GIM will be&#xD;
      performed based on the Operative Link for GIM scoring system.&#xD;
&#xD;
      To achieve Aim 2, patients with histologically-confirmed GIM (N=300) will be followed&#xD;
      longitudinally. Biennial endoscopic surveillance will be performed, with repeat biopsies,&#xD;
      specimen collection, and histologic scoring. Progression of GIM will be defined as upstaging&#xD;
      of GIM score, or development of either dysplasia or carcinoma on any biopsy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 30, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression of intestinal metaplasia</measure>
    <time_frame>24 months following enrollment</time_frame>
    <description>Progression will be assessed using the Operative Link for Gastric Intestinal Metaplasia (Reference 1). This score reflects both the histologic severity as well as anatomic location of intestinal metaplasia. Scores range from 0 (no metaplasia) to 4 (severe metaplasia). It is believed that higher scores portend a higher risk for progression to cancer.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Intestinal Metaplasia of Gastric Mucosa</condition>
  <condition>Helicobacter Pylori Infection</condition>
  <condition>Atrophic Gastritis</condition>
  <arm_group>
    <arm_group_label>Gastric intestinal metaplasia</arm_group_label>
    <description>Subjects with histologically-confirmed intestinal metaplasia found during endoscopy with protocoled biopsies.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Subjects without intestinal metaplasia found during endoscopy with protocoled biopsies (age and sex matched to cases)</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Saliva Blood Gastric specimens&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        As above&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: Subjects between the ages of 35 and 84, who are undergoing outpatient&#xD;
        endoscopy for the following indications are eligible: abdominal pain, dyspepsia, iron&#xD;
        deficiency anemia, Helicobacter assessment, surveillance of suspected or known intestinal&#xD;
        metaplasia, evaluation for family history of gastric cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cannot give consent&#xD;
&#xD;
          -  Have history of gastric surgery&#xD;
&#xD;
          -  Have history of solid tumor or bone marrow transplant&#xD;
&#xD;
          -  Platelet Count &lt; 70 or international normalized ratio &gt; 1.5&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Robert J Huang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joo Ha Hwang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert J Huang, MD</last_name>
    <phone>650-725-0634</phone>
    <email>rjhuang@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert J Huang, MD</last_name>
      <phone>650-725-0634</phone>
      <email>rjhuang@stanford.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 5, 2019</study_first_submitted>
  <study_first_submitted_qc>December 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2019</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Robert Huang</investigator_full_name>
    <investigator_title>Instructor of Medicine, Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Precancerous Conditions</mesh_term>
    <mesh_term>Gastritis</mesh_term>
    <mesh_term>Gastritis, Atrophic</mesh_term>
    <mesh_term>Metaplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

